دورية أكاديمية
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
| العنوان: | Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. |
|---|---|
| المؤلفون: | Silbermann R; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Laubach J; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA., Kaufman JL; Department of Mematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Sborov DW; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA., Reeves B; Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA., Rodriguez C; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Chari A; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Costa LJ; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Anderson LD Jr; Division of Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Texas Southwestern Medical Center, Dallas, Texas, USA., Nathwani N; Division of Myeloma, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Shah N; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Holstein SA; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA., Costello C; Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, California, USA., Jakubowiak A; Medicine- Hematology and Oncology, University of Chicago, Chicago, Illinois, USA., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Cowan AJ; Department of Medicine, University of Washington, Seattle, Washington, USA., Gries KS; Janssen Research & Development, Raritan, New Jersey, USA., Pei H; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Voorhees PM; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA., Usmani SZ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Richardson PG; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA. |
| المصدر: | American journal of hematology [Am J Hematol] 2024 Jul; Vol. 99 (7), pp. 1257-1268. Date of Electronic Publication: 2024 Apr 15. |
| نوع المنشور: | Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Blackwell Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | Multiple Myeloma*/drug therapy , Quality of Life* , Bortezomib*/administration & dosage , Bortezomib*/therapeutic use , Dexamethasone*/administration & dosage , Dexamethasone*/therapeutic use , Lenalidomide*/administration & dosage , Lenalidomide*/therapeutic use , Patient Reported Outcome Measures* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult |
| مستخلص: | In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) improved depth of response and progression-free survival (PFS) versus lenalidomide, bortezomib, and dexamethasone (RVd) alone in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) collected using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30-item (QLQ-C30), EORTC Quality of Life Questionnaire Multiple Myeloma Module 20-item (QLQ-MY20), and EuroQol 5-Dimension 5-Level (EQ-5D-5L) tools on day 1 of cycles 1, 2, and 3; on day 21 of cycle 4 (end of induction therapy); on day 1 of cycle 5; on day 21 of cycle 6 (end of posttransplant consolidation therapy); and at months 6, 12, 18, and 24 of maintenance therapy. Meaningful improvements from baseline were seen in most of the PRO scales with both treatments after consolidation and were sustained for at least 2 years of maintenance treatment. Large reductions from baseline (~20 points) were especially observed in pain symptoms for both treatment groups, although these were numerically higher for patients receiving D-RVd during the majority of the time points. In addition, improvements in key scales, such as global health status, fatigue symptoms, and physical functioning, were also seen with both D-RVd and RVd. These improvements in health-related quality of life contribute to the totality of evidence supporting the improvement in clinical outcomes such as response rates and PFS with D-RVd in induction, consolidation, and maintenance therapy in TE patients with NDMM. (© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.) |
| References: | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7‐30. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA‐ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Hemasphere. 2021;5(2):e528. DARZALEX®. Prescribing information. Janssen Biotech, Inc. 2015. Accessed February 20, 2023. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf. European Medicines Agency. DARZALEX 20 mg/mL concentrate for solution for infusion. Summary of product characteristics. 2016. Accessed February 20, 2023. https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf. DARZALEX FASPRO®. Prescribing information. Janssen Biotech, Inc. 2021. Accessed February 2, 2023. https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/DARZALEX+Faspro‐pi.pdf. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant‐eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936‐945. Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation‐eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open‐label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):e825‐e837. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2023;390(4):301‐313. Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21. Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta‐analysis. Eur J Haematol. 2016;97(5):416‐429. Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient‐reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book. 2018;38:122‐134. Curran D, Cabrera ES, Nelsen L. Patient‐reported outcomes in vaccines research: relevance for decision‐making. Hum Vaccin Immunother. 2022;18(1):1‐8. Powers JH 3rd, Howard K, Saretsky T, et al. Patient‐reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis. 2016;63(suppl 2):s52‐s56. Wisløff F, Eika S, Hippe E, et al. Measurement of health‐related quality of life in multiple myeloma. Br J Haematol. 1996;92(3):604‐613. Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease‐specific questionnaire module (the QLQ‐MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670‐1678. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five‐level version of EQ‐5D (EQ‐5D‐5L). Qual Life Res. 2011;20(10):1727‐1736. Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality‐of‐life questionnaires: a comparison of the EORTC QLQ‐C30 cancer‐specific questionnaire to the generic utility questionnaires EQ‐5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87(4):330‐337. Sully K, Trigg A, Bonner N, et al. Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients. Eur J Haematol. 2019;103(5):500‐509. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ‐5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ‐C30 Scoring Manual. Vol 3. European Organisation for Research and Treatment of Cancer; 2001. Nielsen LK, Larsen RF, Jarlbaek L, Möller S, Jespersen E. Health‐related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program. Ann Hematol. 2021;100(9):2311‐2323. Engelhardt M, Ihorst G, Singh M, et al. Real‐world evaluation of health‐related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021;21(2):e160‐e175. Coleman EA, Goodwin JA, Coon SK, et al. Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs. 2011;34(3):219‐227. LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK. How are patient‐reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. Qual Life Res. 2020;29(6):1419‐1431. Bhutani M, Lonial S, Mikhael J. Disparities in multiple myeloma among African Americans. J Natl Med Assoc. 2023;115(2S):S26‐S31. Roussel M, Hebraud B, Hulin C, et al. Health‐related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020;61(6):1323‐1333. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132‐147. Perrot A, Facon T, Plesner T, et al. Health‐related quality of life in transplant‐ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial. J Clin Oncol. 2021;39(3):227‐237. Roussel M, Moreau P, Hebraud B, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation‐eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health‐related quality of life outcomes of a randomised, open‐label, phase 3 trial. Lancet Haematol. 2020;7(12):e874‐e883. Fernandes LL, Zhou J, Kanapuru B, et al. Review of patient‐reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement. Blood Cancer J. 2021;11(8):148. Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real‐world setting. Blood Cancer J. 2018;8(11):109. |
| معلومات مُعتمدة: | Alliance Foundation Trials; Janssen Oncology |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02874742 |
| المشرفين على المادة: | 69G8BD63PP (Bortezomib) 7S5I7G3JQL (Dexamethasone) F0P408N6V4 (Lenalidomide) 4Z63YK6E0E (daratumumab) 0 (Antibodies, Monoclonal) |
| تواريخ الأحداث: | Date Created: 20240416 Date Completed: 20240611 Latest Revision: 20240611 |
| رمز التحديث: | 20240611 |
| DOI: | 10.1002/ajh.27326 |
| PMID: | 38622840 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-8652 |
|---|---|
| DOI: | 10.1002/ajh.27326 |